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the preclinical amyloid sensitive 
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Alzheimer’s disease
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Seong Hye choi4, Byeong C. Kim5, Kyung Won Park6, Duk L. Na1,2,7, Juhee Chin1,2,12* & 
Sang Won Seo1,2,8,9,10,11,12*
Recently, the focus of Alzheimer’s disease (AD) research has shifted from the clinical stage to the 
preclinical stage. We, therefore, aimed to develop a cognitive composite score that can detect 
the subtle cognitive differences between the amyloid positive (Aβ+) and negative (Aβ−) status 
in cognitively normal (CN) participants. A total of 423 CN participants with Aβ positron emission 
tomography images were recruited. The multiple-indicators multiple-causes model found the latent 
mean difference between the Aβ+ and Aβ− groups in the domains of verbal memory, visual memory, 
and executive functions. The multivariate analysis of covariance (MANCOVA) showed that the 
Aβ+ group performed worse in tests related to the verbal and visual delayed recall, semantic verbal 
fluency, and inhibition of cognitive inference within the three cognitive domains. The Preclinical 
Amyloid Sensitive Composite (PASC) model we developed using the result of MANCOVA and the 
MMSE presented a good fit with the data. The accuracy of the PASC score when applied with age, sex, 
education, and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% 
CI = 0.667–0.860) in the external validation set (N = 179). We conclude that the PASC can eventually 
contribute to facilitating more prevention trials in preclinical AD.
With the advancement of amyloid-β (Aβ) positron emission tomography (PET), the focus of research on Alz-
heimer’s disease (AD) has shifted from the clinical and symptomatic stages to the preclinical and asymptomatic 
stages of  AD1. Consequently, approximately 20–30% of cognitively normal (CN) elderly population appear to 
be CN individuals with Aβ  positivity2–4. These CN individuals with elevated amyloidosis are considered to be 
more vulnerable to AD progression. This can be demonstrated by the subtle cognitive difference between CN 
individuals with amyloid positivity and those without Aβ biomarkers in the late preclinical  stage5. Furthermore, 
several reports have claimed that approximately 25% of Aβ+ CN individuals converts to mild cognitive impair-
ments (MCI) or dementia in approximately 3  years6,7.
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Although Aβ PET has such advantage of early detection of Aβ+ biomarker, it is usually challenging to obtain 
a large number of participants with PET data due to the high cost and safety concerns. However, the importance 
of Aβ biomarker has kept rising as several prevention trials are currently being conducted in preclinical AD 
with the expectation to target Aβ. Thus, it will be pragmatic and essential for clinicians to predict who might be 
at high risk of having an Aβ+ biomarker without the help of neuroimaging techniques. As a result, we need to, 
instead, investigate the distinct neuropsychological features of CN who have elevated Aβ, which may help clini-
cians predict preclinical AD by reducing screen failures and monitoring the therapeutic efficacy of prevention.
Previously, there were several attempts to investigate the distinct neuropsychological features of Aβ+ CN 
individuals. However, the results were inconsistent among studies to date. Multiple studies have consistently 
reported that high amyloid burden in CN adults is associated with poorer performance in episodic  memory8,9. 
On the other hand, a large lifespan study of CN adults found association of amyloid deposition with executive 
functions, but not with memory  burden10. This discrepancy may be because not many previous studies considered 
the effects of measurement errors, although there is always a possibility for the presence of measurement errors 
in  psychometrics11. In fact, there was a study considered measurement errors using structural equation modeling 
(SEM) to examine the associations between amyloid burden or white matter hyperintensity and  cognition9. 
However, there are still few studies considering the effects of measurement errors in studying biomarkers and 
cognition together, and there is a need to build more evidence for this methodology in this regard. Accordingly, 
we used the multiple-indicators multiple-causes (MIMIC) model in our study to examine Aβ related cognitive 
functions. By using the principle of factor analysis, the MIMIC model can control for these measurement errors 
to estimate the latent values. That is, MIMIC may empower a composite model to sensitively detect subtle cog-
nitive differences between Aβ+ and Aβ− in CN elderlies. However, to our knowledge, no Aβ+ CN studies have 
yet applied this factor structure method to develop a cognitive composite model for identifying preclinical AD 
in the elderly population.
In the present study, we aimed to determine if there are any distinct cognitive domains and cognitive meas-
ures of Aβ+ CN using the MIMIC model, which may yield lower background noise in measurements. We also 
developed the Preclinical Amyloid Sensitive Composite (PASC) model, a composite model that precisely dis-
tinguishes cognitive differences between Aβ+ and Aβ− in CN individuals. Then, we computed the PASC score 
employing the PASC model we developed. Finally, we validated the PASC score along with age, sex, education, 
and APOE ε4 to distinguish between Aβ+ and Aβ− CN in an external validation set. Considering that subtle 
deficits in episodic memory and executive functions appear to be critical in preclinical AD due to their strong 
association with AD  progression12, we hypothesized that the PASC score consisting of memory and executive 
functions might differentiate Aβ+ CN from Aβ− CN with adequate accuracy.
Results
Demographic characteristics of participants. The demographic and neuropsychological characteris-
tics of the study participants are presented in Table 1. The overall mean age of the participants was 69.9 years. 
Among the 423 participants, 75 were Aβ+ (17.7%). The frequency of APOE ε4 carriers was 24.6%. The Aβ+ group 
was significantly older than the Aβ− group (71.5 ± 6.8 years vs. 69.5 ± 8.4 years, p < 0.05). The Aβ+ group also 
displayed a higher percentage of APOE ε4 carriers compared with the Aβ− group (58.0% vs. 17.5%, p < 0.001). 
However, the two groups did not significantly differ in education level and proportion of female participants.
MIMIC model for latent mean analysis. The confirmatory factor analysis (CFA) model was success-
fully validated to control measurement errors. Accordingly, error covariance was added between the residual 
variances associated with the Seoul Verbal Learning Test-Elderly’s version (SVLT-E) immediate and delayed 
recalls and the Rey-Osterrieth Complex Figure Test (RCFT) immediate and delayed recalls. The CFA model with 
added error covariance fit the data well (χ2 = 212.181, df = 78, p < 0.001; RMSEA = 0.064; CFI = 0.957; TLI = 0.942; 
SRMR = 0.056). All factor loadings in the model were significant between 0.49 and 0.89. Next, a latent mean dif-
ference between Aβ+ and Aβ− for each cognitive domain was verified. The latent mean model fit the data well 
(χ2 = 359.481, df = 128, p < 0.001; RMSEA = 0.065; CFI = 0.944; TLI = 0.919; SRMR = 0.048). The result revealed 
that the differences between the Aβ+ and Aβ− groups in attention, visuospatial function, and language function 
were not significant, but the latent means in the Aβ+ group were significantly lower than the Aβ− group in the 
three domains of verbal memory, visual memory, and executive functions (Table 2).
MANCOVA. Based on the results above, further statistical analyses were conducted for each neuropsycho-
logical assessment within the episodic memory and executive functions. Multivariate analysis of covariance 
(MANCOVA) was used to see the score differences of the tests under episodic memory and executive functions 
between the Aβ+ and Aβ− groups when sex, education, and age were controlled. The result of the MANCOVA 
is shown in Table 3. Few neuropsychological subtests showed meaningful differences between the groups. Pri-
marily, we set the level of significance at 0.1. Regarding episodic memory, the SVLT-E delayed recall showed a 
difference in score between the Aβ+ and Aβ− groups (F(1, 418) = 3.666, p = 0.056). For the RCFT, the Aβ+ group 
performed worse, not only on the delayed recall (F(1, 418) = 4.036, p = 0.045), but also on the immediate recall 
(F(1,418) = 2.898, p = 0.089). However, due to the extremely high correlation between the two subtests (r = 0.935), 
we considered that it would be reasonable to use only one subset in our composite model. Based on the clinical 
and statistical significance, the RCFT delayed recall was favored over the RCFT immediate recall for the PASC. 
In terms of executive functions, the Korean-Color Word Stroop test (K-CWST) color reading (F(1, 418) = 4.745, 
p = 0.030) and the Controlled Oral Word Association Test (COWAT) animal naming showed worse performance 
in the Aβ+ group compared to that in the Aβ− group (F(1, 418) = 3.152, p = 0.077).
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Table 1.  Demographic and neuropsychological characteristics of the study  participantsa. N, number; APOE 
ε4, Apolipoprotein E; Aβ, amyloid-β; K-BNT, the Korean version of the Boston Naming Test; CDT, the Clock 
Drawing Test; RCFT, the Rey-Osterrieth Complex Figure Test; SVLT-E, the Seoul Verbal Learning Test-
Elderly’s version; COWAT, the Controlled Oral Word Association Test; K-CWST, the Korean Color Word 
Stroop Test; DSC, Digit Symbol Coding; K-TMT-E-A, the Korean Trail Making Test-Elderly’s version part A; 
K-TMT-E-B, the Korean Trail Making Test-Elderly’s version part B; K-MMSE, the Korean Mini-Mental State 
Examination. **p < 0.05 between Aβ− and Aβ+ in both sets. a Values are presented as mean (standard deviation) 
or number (%). b The Independent sample t-test was used for continuous variables, and the chi-square test 
was used for categorical variables. c Analysis of covariance was conducted as a statistical analysis to see the 
difference in test scores of each group. Age, education, and sex were adjusted as covariates in the analysis. 
d APOE ε4 genotyping: development set N = 395; validation set N = 167.
Development set Validation set
All (N = 423) Aβ− (N = 348) Aβ+ (N = 75) All (N = 179) Aβ− (N = 150) Aβ+ (N = 29)
Demographicsb
Age, years** 69.9 (8.1) 69.5 (8.4) 71.5 (6.8) 69.4 (8.2) 68.6 (8.2) 73.7 (6.8)
Education, years 11.8 (4.8) 11.9 (4.8) 11.3 (4.5) 12.0 (4.4) 12.1 (4.5) 11.9 (4.1)
Female, N (%) 267 (63.1) 219 (62.9) 48 (64) 108 (60.3) 91 (60.7) 17 (58.6)
APOE ε4 carrier N (%)d** 97 (24.6) 57 (17.5) 40 (58.0) 38 (22.8) 24 (17.1) 14 (51.9)
Neuropsychological testsc
Attention
 Digit span forward 6.3 (1.4) 6.3 (1.4) 6.2 (1.3) 6.5 (1.5) 6.5 (1.5) 6.6 (1.4)
 Digit span backward 4.1 (1.3) 4.1 (1.4) 4.0 (1.1) 4.4 (1.5) 4.4 (1.5) 4.5 (1.7)
Language
 K-BNT 48.6 (6.7) 48.8 (6.6) 47.7 (7.2) 50.2 (5.3) 50.3 (5.3) 49.2 (5.5)
Visuospatial functions
 RCFT copy 32.7 (3.6) 32.7 (3.7) 32.5 (3.1) 32.9 (2.7) 32.9 (2.6) 32.7 (3.2)
 CDT 2.8 (0.5) 2.8 (0.5) 2.8 (0.4) 2.9 (0.4) 2.9 (0.4) 2.9 (0.3)
Memory
 SVLT-E immediate recall 21.4 (4.6) 21.6 (4.6) 20.4 (4.4) 21.7 (4.4) 22.0 (4.4) 19.9 (4.2)
 SVLT-E delayed recall 7.0 (2.1) 7.1 (2.1) 6.4 (2.0) 7.1 (2.0) 7.3 (2.0) 6.0 (1.7)
 SVLT-E recognition 21.2 (2.0) 21.3 (1.9) 20.8 (2.0) 21.4 (1.6) 21.5 (1.6) 20.8 (1.4)
 RCFT immediate recall 14.9 (7.2) 15.3 (7.2) 13.1 (7.4) 16.4 (6.6) 16.7 (6.4) 14.8 (7.1)
 RCFT delayed recall 14.8 (6.8) 15.2 (6.7) 12.9 (7.1) 15.9 (6.1) 16.2 (6.0) 14.0 (6.0)
 RCFT recognition 19.6 (2.2) 19.7 (2.2) 19.2 (2.2) 20.1 (1.8) 20.2 (1.9) 19.6 (1.3)
Frontal/executive functions
 COWAT animal 15.9 (4.8) 16.1 (4.9) 14.7 (4.3) 16.8 (4.3) 16.7 (4.4) 17.3 (4.2)
 COWAT phonemic total 27.2 (11.8) 27.6 (11.8) 25.4 (12.0) 29.2 (10.9) 29.0 (11.1) 30.0 (9.8)
 K-CWST color reading 87.1 (21.2) 88.6 (21.2) 80.7 (20.3) 89.9 (19.8) 91.6 (19.1) 81.1 (21.7)
 DSC 53.1 (19.5) 54.2 (19.8) 48.3 (17.1) 57.5 (19.7) 58.6 (19.6) 51.9 (19.6)
 K-TMT-E-A time, s 24.6 (13.1) 24.1 (13.3) 26.9 (11.9) 22.0 (10.5) 21.7 (10.8) 23.0 (8.7)
 K-TMT-E-B time, s 56.5 (54.1) 55.2 (54.3) 62.7 (53.1) 41.6 (30.7) 39.6 (30.9) 51.6 (27.7)
Others
 K-MMSE 28.1 (1.8) 28.2 (1.8) 27.7 (1.5) 28.4 (1.6) 28.4 (1.5) 28.5 (2.3)
Table 2.  Latent mean difference between amyloid positive and negative groups for neuropsychological 
domains. Sex, education, and age were adjusted as covariates in the analyses. K-BNT, the Korean Boston 
Naming Test; Frontal EF, frontal executive functions; SE, standard error; 95% CI, 95% Confidence Interval.
Neuropsychological domains Estimate SE Bias-corrected bootstrap percentile (95% CI)
Amyloid positivity → Attention 0.040 0.114 (− 0.168, 0.282)
Amyloid positivity → Visuospatial function 0.159 0.375 (− 0.657, 0.814)
Amyloid positivity → K-BNT − 0.017 0.782 (− 1.961, 1.122)
Amyloid positivity → Verbal memory − 0.809 0.345 (− 1.662, − 0.213)
Amyloid positivity → Visual memory − 1.449 0.724 (− 3.004, − 0.233)
Amyloid positivity → Frontal EF − 0.440 0.213 (− 1.109, − 0.094)
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Development of the preclinical amyloid sensitive composite (PASC) model. Based on the MAN-
COVA results and the literature, the following 5 tests were finally selected: the SVLT-E delayed recall; the RCFT 
delayed recall; the K-CWST color reading; the COWAT animal naming; and the Korean Mini-Mental State Exam-
ination (K-MMSE). The K-MMSE was added for examining global cognition. The PASC CFA model presented 
a good fit with the data (χ2 = 4.757, df = 5, p = 0.933; RMSEA < 0.001; CFI = 1.000; TLI = 1.001; SRMR = 0.014). 
All factor loadings in the model were significant between 0.56 and 0.73 (Fig. 1). The MIMIC model was used to 
ensure that the PASC distinguished between Aβ+ and Aβ− (Fig. 2). Our MIMIC model for the PASC fit the data 
well (χ2 = 56.526, df = 21, p < 0.001; RMSEA = 0.063; CFI = 0.955; TLI = 0.936; SRMR = 0.036). The result showed 
that the latent mean in the Aβ+ group was significantly lower than the Aβ− group (t = -2.340, p = 0.019) (Table 4). 
Calculation of the PASC score. In order to create the composite score, we implemented the principal 
component analysis (PCA) with the z-scores of the 5 tests. As a result, the following composite equation was 
generated:
Table 3.  MANCOVA with neuropsychological tests in Memory and Executive Functions. Sex, education, and 
age were adjusted as covariates in the analyses. RCFT, the Rey-Osterrieth Complex Figure Test; SVLT-E, the 
Seoul Verbal Learning Test-Elderly’s version; COWAT, the Controlled Oral Word Association Test; K-CWST, 
the Korean Color Word Stroop Test; DSC, Digit Symbol Coding; K-TMT-E-B, the Korean Trail Making Test-
Elderly’s version part B. *p < 0.1
Wilks’ Lambda Mean Square F p value
Verbal memory 0.991 1.274 0.283
SVLT-E immediate recall 31.149 2.007 0.157
SVLT-E delayed recall* 11.700 3.666 0.056
SVLT-E recognition 4.760 1.564 0.212
Visual memory 0.989 1.595 0.190
RCFT immediate recall* 110.640 2.898 0.089
RCFT delayed recall* 132.980 4.036 0.045
RCFT recognition 5.195 1.263 0.262
Executive functions 0.981 1.602 0.161
COWAT animal* 57.491 3.152 0.077
COWAT phonemic total 40.766 0.416 0.560
K-CWST color reading* 1,305.356 4.745 0.030
DSC 436.424 2.303 0.178
K-TMT-E-B time 100.874 0.052 0.843
Figure 1.  The CFA model of the PASC. Abbreviations: CFA, Confirmatory Factor Analysis; PASC, the 
Preclinical Amyloid Sensitive Composite; SVLT delayed, the Seoul Verbal Learning Test-Elderly’s version 
delayed recall; RCFT delayed, the Rey-Osterrieth Complex Figure Test delayed recall; STROOP CR, the Stroop 
color reading test; COWAT animal, the Controlled Oral Word Association Test animal naming; MMSE, the 
Mini-Mental State Examination; err, error.
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The receiver operating characteristic (ROC) curve analysis presented a decent accuracy for the PASC score 














Figure 2.  The MIMIC model of the PASC for latent mean comparison between Aβ+ and Aβ− cognitively 
normal participants. For amyloid positivity, 0 and 1 indicate Aβ− and Aβ+ respectively. Age, education, and 
APOE ε4 were adjusted as covariates. Abbreviations: MIMIC, Multiple-Indicators Multiple-Causes; PASC, 
the Preclinical Amyloid Sensitive Composite; Aβ, amyloid-β; APOE ε4, Apolipoprotein E; SVLT delayed, the 
Seoul Verbal Learning Test-Elderly’s version delayed recall; RCFT delayed, the Rey-Osterrieth Complex Figure 
Test delayed recall; STROOP CR, the Stroop color reading test; COWAT animal, the Controlled Oral Word 
Association Test animal naming; MMSE, the Mini-Mental State Examination; err, error.
Table 4.  Latent mean difference between amyloid positive and negative groups for PASC. Education, age, and 
APOE ε4 were adjusted as covariates in the analyses. PASC, the Preclinical Amyloid Sensitive Composite; SE, 
Standard Error; 95% CI, 95% Confidence Interval. *p < 0.05.
Latent mean difference Estimate SE Bias-corrected bootstrap percentile (95% CI)
Amyloid positivity → PASC − 0.345* 0.147 (− 0.641, − 0.049)
Figure 3.  The ROC curve analysis of the PASC score, age, sex, education, and APOE ε4 in the development (A) 
and validation (B) sets. Abbreviations: ROC, Receiver Operating Characteristic; PASC, the Preclinical Amyloid 
Sensitive Composite; APOE ε4, Apolipoprotein E; AUC, Area Under the Curve.
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CI = 0.704–0.837) (Fig. 3a, Table 5). The sensitivity (71%) and specificity (73.5%) were optimal for distinguishing 
between Aβ+ and Aβ−, and the Youden index was 0.445.
External validation. The demographic and neuropsychological features of the validation sample are 
described in Table 1. The overall mean age of the validation set was comparable with that of the development set 
(69.4 ± 8.2 years vs. 69.9 ± 8.1, p = 0.494). Similarly, the years of education in the validation set were not different 
from those in the development set (12.0 ± 4.4 vs. 11.8 ± 4.8, p = 0.527). The proportion of female in the validation 
sample also did not differ from that in the development sample (60.3% vs. 63.1%, p = 0.519). Moreover, the rate 
of Aβ+ of the validation sample was similar to that of the development sample (16.2% vs. 17.7%, p = 0.650). The 
proportion of APOE ε4 carriers in the validation set was also at comparable levels to that in the development set 
(22.8% vs. 24.6%, p = 0.648). Within the validation sample, the Aβ+ group was significantly older than the Aβ− 
group (73.7 years vs. 68.6 years, p < 0.05). The Aβ+ group also displayed a higher percentage of APOE ε4 carriers 
compared with the Aβ− group (51.9% vs. 17.1%, p < 0.001). However, the two groups did not significantly differ 
in education level and proportion of female participants. The PASC CFA model exhibited a good fit with the vali-
dation sample (χ2 = 2.338, df = 5, p = 0.801; RMSEA < 0.001; CFI = 1.000; TLI = 1.028; SRMR = 0.016). The MIMIC 
model for the PASC showed a fair fit to the validation sample (χ2 = 49.870, df = 21, p < 0.001; RMSEA = 0.088; 
CFI = 0.917; TLI = 0.882; SRMR = 0.051). The accuracy of the PASC score when applied with age, sex, education, 
and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% CI = 0.667–0.860). The 
sensitivity and specificity were also optimal when the Youden index was 0.402 (sensitivity = 70.4%; specific-
ity = 69.8%) (Fig. 3b, Table 5). The results of the ROC curve analysis in the external validation set were compara-
ble to those in the development set (Table 5).
Discussion
We investigated the distinct neuropsychological features of Aβ+ CN elderlies in a carefully phenotyped, CN 
cohort that underwent detailed neuropsychological tests, MRI, and amyloid PET scans with the standardized 
protocols. Accordingly, there were several significant neuropsychological findings in this study. First, the MIMIC 
model found the latent mean difference between the Aβ+ and Aβ− groups in the domains of verbal memory, 
visual memory, and executive functions. Furthermore, MANCOVA showed that the Aβ+ group performed worse 
in the SVLT-E delayed recall, the RCFT delayed recall, the K-CWST color reading, and the COWAT animal 
naming within the three cognitive domains. The PASC model that we developed using the result of MANCOVA 
and the MMSE presented a good fit with the data. Finally, the accuracy of the PASC score when applied with 
age, sex, education, and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% 
CI = 0.667–0.860) in the external validation set (N = 179). Our results, therefore, suggested that the PASC might 
contribute to decreasing financial loss due to screen failures in preclinical AD clinical trials and facilitating more 
prevention trials subsequently.
The demographic profile of our participants was extremely close to that of the previously reported Asian 
society profile. The CN Aβ+ percentage in Asian countries is known to be lower than that in western countries. 
The percentage of CN amyloid positivity in the Asian population ranged between 18 and 25% according to the 
Korean Brain Aging Study for the Elderly Diagnosis and Prediction of Alzheimer’s disease (KBASE) and Japanese 
ADNI (J-ADNI)13,14. On the other hand, the western population, represented by ADNI, was reported to range 
approximately from 25 to 45% Aβ positivity  rate15,16. Our study exhibited approximately 18% Aβ positivity in the 
423 CN individuals, which was in line with that in the Asian population. The discrepancy between our results 
and that of the western society may be explained by the differences in the frequency of APOE ε4 and the age 
of the study participants. Our cohort seemed to have a lower percentage of APOE ε4 (23%) than that reported 
by ADNI (27%)17. Moreover, the younger age of our cohort (mean, 69.9 years) compared to that of the ADNI 
CN individuals (mean, 75.8 years) may have affected the lower rate of amyloid  positivity17. Regardless of these 
disparities, the APOE ε4 rate and the age of our cohort were still at comparable levels to J-ADNI’s APOE ε4 rate 
(24%) and CN individuals’ ages (mean, 67.9)13.
Our major finding was that the Aβ+ CN individuals presented a lower performance in verbal memory, visual 
memory, and executive functions compared to Aβ− CN, which was generally consistent with the findings of 
previous meta-analyses. In terms of memory, there has been a consensus that episodic memory has a strong 
association with Aβ  burden18–20. In our study, delayed recall task of both verbal and visual memory tests especially 
stood out as the performance difference between Aβ+ and Aβ− seem to be more prominent than immediate or 
recognition tasks. This result is not surprising because previous studies with CN or MCI also suggested that using 
delayed recall may be good predictor of Aβ  positivity21,22. Unlike episodic memory, the results regarding execu-
tive functions in the previous studies are not entirely consistent. A recent meta-analysis suggested a significant 
Table 5.  Accuracy of the ROC curve analysis of the PASC score, age, sex, education, and APOE ε4 in the 
development and validation sets. ROC, Receiver Operating Characteristic; PASC, the Preclinical Amyloid 
Sensitive Composite; APOE ε4, Apolipoprotein E; AUC, Area Under the Curve; 95% CI, 95% Confidence 
Interval.
AUC 95% CI Sensitivity (%) Specificity (%)
Development set 0.771 0.704–0.837 71.0 73.5
Validation set 0.764 0.667–0.860 70.4 69.8
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difference in executive  function19, while two others showed either a small effect size or a weak association with 
Aβ  burden18,20. This may be because the previous studies did not consider the effects of measurement errors 
that could impact the individual test scores. However, applying a factor analysis with the latent variables, we 
controlled for the measurement errors from each test score for more precise measurement of the corresponding 
cognitive function.
In the present study, we also developed the PASC that is sensitive to the subtle cognitive differences in CN 
based on amyloid positivity. The PASC comprises the SVLT-E delayed recall, the RCFT delayed recall, the 
COWAT animal naming, and the K-CWST color reading, which were found to be significantly different between 
the two CN groups from the three cognitive domains, and the K-MMSE. We included the K-MMSE in the PASC 
because the Mini-Mental State Exam (MMSE) is a practical neuropsychological test to examine individual cogni-
tive function  holistically23. Global cognition was previously reported to be associated with  amyloidosis7,24–26, and 
has been considered to help with early identification of dementia risk and further cognitive  decline27. Further-
more, other composite scores such as the Preclinical Alzheimer Cognitive Composite (PACC) and the Alzhei-
mer’s Prevention Initiative Composite Cognitive Test Score (APCC) include the MMSE for global functioning 
and orientation  status28–30. In this regard, we included the MMSE for the convenience of harmonization in the 
future international collaboration. In fact, the PASC may seem similar to the PACC 29. However, the PACC has 
been mainly applied to track cognitive changes in preclinical AD over  time25,31, whereas the PASC investigated 
the cognitive difference between Aβ+ CN and Aβ− CN cross-sectionally.
Although AD pathology progression involves the deterioration of multiple cognitive domains, there are a 
few benefits to observe cognitive differences in CN individuals with a single composite that is a unidimensional 
outcome. First, it allows comprehensive yet precise cognitive assessment particularly in preclinical AD. Currently, 
the  MMSE23 and the Clinical Dementia Rating (CDR)32 are commonly used to assess individual cognitive func-
tion holistically. However, they often display ceiling effects in CN  individuals33,34. Therefore, they are not quite 
sensitive measures for CN individuals. Furthermore, the ratings of the CDR primarily rely on clinicians’ judg-
ments following patient and caregiver interviews. In other words, bias is rarely avoidable in the CDR. As a result, 
there is a need for a novel and reliable measure to holistically assess cognitive function specific to preclinical AD, 
and we expect that the PASC can meet the need. Another advantage of obtaining a unidimensional composite is 
that it induces a more precise result in the outcome measurement. Compared to using multi-outcomes, using a 
single outcome usually yields lower background noise in the measurement, which derives a lower risk of Type-I 
 error11,28. Therefore, applying a single primary outcome has better reliability and sensitivity especially in terms 
of detecting subtle cognitive differences in preclinical AD.
The major strength of our study is that we considered measurement errors in the test scores when we imple-
mented the analyses. Another strength is the large sample size of the CN cohort who underwent amyloid PET. 
In spite of these strengths, there are a few limitations to our study. First, the participants went through differ-
ent types of PET ligands. The variety of the tracers may have affected the visual reads of amyloid deposition. 
However, this limitation can be somewhat alleviated by the high correlations among the different  ligands35,36. 
Second, we did not explore the clinical effects of the PASC. Future studies with clinical impacts of the PASC on 
other biomarkers like tau or cortical atrophy may be recommended. Another limitation is that our study used 
dichotomized variable of amyloid burden. The issue about dichotomization of amyloid deposition has been con-
stantly questioned as there were several studies showing longitudinal cognitive decline related to subthreshold 
amyloid in Aβ− CN  individuals37–39. In future studies, continuous measure of amyloid burden may be used to 
embrace the issue of subthreshold amyloid. Also, longitudinal studies using the PASC may be needed to examine 
the clinical applicability related to the issue.
Our study created the PASC which is a sensitive cognitive composite score for Aβ+ in CN elderly individu-
als, subsequent to investigating some distinct cognitive features of Aβ+ in CN elderly individuals. The PASC, 
which employed significant tests in episodic memory and executive functions, along with the global cognitive 
measure of the K-MMSE, showed adequate accuracy when it was applied with age, sex, education, and APOE 
ε4. Therefore, we expect the PASC to be applied potentially into diverse forms of studies such as trial ready 
 registries40,41 and to contribute to decreasing financial loss due to screen failures and facilitating more prevention 
trials subsequently. Moreover, given that the cognitive tests that reflect the characteristics of early preclinical 
AD are anticipated to reflect the later cognitive change, we expect the PASC to be used for monitoring of disease 
progression or therapeutic efficacy.
Methods
Study participants. A total of 423 CN participants were recruited from September 2015 to December 
2018 at the Samsung Medical Center in Seoul, South Korea. All the participants met the following criteria to be 
qualified as CN: (a) the K-MMSE 24 or above -1.5 standard deviation (SD) from the age-, sex-, and education-
adjusted norms if the education period was less than 9 years; (b) above -1 SD from the age-, sex-, and education-
adjusted norms on the delayed recall of the SVLT-E; (c) above -2 SD from the age-, sex-, and education-adjusted 
norms on the Korean version of the Boston Naming Test (K-BNT), the RCFT copy, and the K-CWST color read-
ing; and (d) an absence of other neurological disorders. The screenings were conducted by trained clinicians and 
neuropsychologists. Brain MRI confirmed the absence of structural lesions, including territorial cerebral infarc-
tion, brain tumors, hippocampal sclerosis, vascular malformation, and cerebral amyloid angiopathy (CAA).
The external validation sample involved 91 CN participants who were recruited from December 2018 to 
April 2020 at the Samsung Medical Center and 88 CN participants who were recruited from May 2017 to April 
2020 at Gangnam Severance Hospital. None of the participants in the external validation sample was included 
in the original study sample.
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Written informed consents were obtained from each participant. This study was approved by the Institutional 
Review Board at the Samsung Medical Center. All methods were implemented in accordance with the approved 
guidelines.
18F-labeled amyloid PET acquisition and analysis. A total of 423 CN participants underwent 
18F-labelled amyloid PET; 219 underwent 18F-florbetaben PET, 203 underwent 18F-flutemetamol PET, and 1 
underwent 18F- florbetapir PET scanning at the Samsung Medical Center. The scanning was performed using 
a Discovery Ste PET/CT scanner (GE Medical Systems, Milwaukee, WI, USA) with a 3D scanning mode that 
examined 47 slices of 3.3 mm thickness spanning the entire brain. Prior to a 20-min emission PET scan with 
dynamic mode consisting of 4 × 5 min frames, 311.5 MBq 18F-florbetaben, 197.7 MBq 18F-flutemetamol, and 
370 MBq 18F-florbetapir were injected. The scan was performed 90 min after the injection. 3D PET images were 
reconstructed in a 128 × 128 × 48 matrix with a 2 × 2 × 3.27 mm voxel size using the ordered-subsets expecta-
tion–maximization algorithm (18F-florbetaben, iteration = 4 and subset = 20; 18F-flutemetamol, iteration = 4 and 
subset = 20; 18F-florbetapir, iteration = 4 and subset = 16).
Visual assessment was done by three experienced raters (two nuclear medicine doctors and one neurologist) 
who were blinded to patient information, and the assessment was dichotomized as Aβ+ or Aβ− using visual reads. 
The visual assessments for 18F-florbetaben PET, 18F-flutemetamol PET, and 18F-florbetapir PET were performed 
with the scoring system that was used in the previous  studies42–46. Inter-rater agreement was excellent for both 
Figure 4.  The MIMIC model of the SNSB-II. The model was created for latent mean comparisons in the 
cognitive domains between Aβ+ and Aβ−. For amyloid positivity, 0 and 1 indicate Aβ− and Aβ+ respectively. 
Age, sex, and education were adjusted as covariates. Abbreviations: MIMIC, Multiple-Indicators Multiple-
Causes; SNSB-II, the second edition of the Seoul Neuropsychological Screening Battery; Frontal EF, Frontal 
Executive Functions; DST, Digit Span Test; RCFT copy, the Rey-Osterrieth Complex Figure Test copy figure; 
CDT, the Clock Drawing Test; BNT, the Boston Naming Test; SVLT immediate, the Seoul Verbal Learning 
Test-Elderly’s version immediate recall; SVLT delayed, the Seoul Verbal Learning Test-Elderly’s version delayed 
recall; SVLT recognition, the Seoul Verbal Learning Test-Elderly’s version recognition; RCFT immediate, the 
Rey-Osterrieth Complex Figure Test immediate recall; RCFT delayed, the Rey-Osterrieth Complex Figure Test 
delayed recall; RCFT recognition, the Rey-Osterrieth Complex Figure Test recognition; COWAT, the Controlled 
Oral Word Association Test; STROOP color, the Stroop color reading test; DSC, Digit Symbol Coding; TMT-B, 
the Trail Making Test-Elderly’s version part B; err, error.
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FBB (Fleiss k = 0.86) and for FMM (Fleiss k = 0.78). After the raters individually rated, we determined the final 
visual positivity based on the majority visual reading result. Also, both FBB and FMM showed the high concord-
ance rates between visual assessment and SUVR cutoff categorization for Aβ deposit (93.5% in FBB and 91.6% 
in FMM). The raters had successfully completed the electronic training program provided by the manufacturer 
to be qualified for the visual assessment.
Neuropsychological assessments. The second edition of the Seoul Neuropsychological Screening Bat-
tery (SNSB-II) was administered to all the participants to assess their cognitive  functions47,48. The SNSB-II was 
standardized on 1,067 CN elderly individuals in South  Korea48. The normative data for the individual neuropsy-
chological test was established based on a representative of South Korean population with age between 45 and 90 
and the education level over 18 years. In our study, we used the following tests that are included in the SNSB-II: 
Digit Span Test (DST) forward and backward for attention; the K-BNT for language; the Clock Drawing Test 
(CDT) and the RCFT for visuospatial function and visual memory; the SVLT-E for verbal memory; and phone-
mic and semantic COWAT, K-CWST, Digit Symbol Coding (DSC), and the Korean Trail Making Test-Elderly’s 
version (K-TMT-E) for executive functions. The RCFT involved copying, immediate recall, 20-min delayed 
recall, and recognition tests. Similarly, the SVLT-E was composed of immediate recall trials, delayed recall, and 
recognition tests. In addition to the tests mentioned above, the K-MMSE was also used for the global mental 
state assessments of the  participants49.
Statistical analyses. Demographic characteristics were compared between the Aβ+ and Aβ− groups using 
the independent sample t-test if the variables were continuous and the chi-square test if the variables were cat-
egorical.
CFA was yielded to validate the structure of the five cognitive domains. CFA is one of the multiple forms of 
SEM, which confirms whether a pre-specified factor structure fits the data  well11. We validated the CFA model 
for the neuropsychological test battery to control for measurement errors. The tests included in each cognitive 
domain were the same as those described earlier, and the language domain consisted of a single test score. The 
subtests of the SVLT-E and the RCFT in the memory domain were measured respectively using the same method. 
Therefore, it was considered acceptable to add an error covariance between the residual variances associated 
with the SVLT-E immediate and delayed recalls and the RCFT immediate and delayed recalls. Since our factor 
structure included both reflective and causal indicators, we used the MIMIC model to compare the latent means 
in the cognitive domains between the Aβ+ and Aβ− groups (Fig. 4).
MANCOVA was performed to see if any neuropsychological tests showed a significant difference between the 
two groups. Since the measurement errors were not treated in the MANCOVA, we deliberately set the cutoff for 
significance to be less conservative in order to increase the power and reduce the risk of type II errors. Thus, the 
tests with p-value < 0.1 were selected to be included in the composite model. The MIMIC model was repeated to 
identify whether these tests were sensitive to differences between Aβ+ and Aβ− in CN elderlies as a composite. 
For the PASC score equation, the PCA was used to obtain the weight for each test score. Accuracy, sensitivity, 
and specificity of the PASC score combined with age, sex, education, and APOE ε4 for distinguishing between 
Aβ+ and Aβ− were tested by ROC analysis.
The CFA and the MIMIC models of the PASC were validated in the cross-validation sample. The accuracy 
for distinguishing between Aβ+ and Aβ− of the PASC score combined with age, sex, education, and APOE ε4 
was investigated by the ROC curve analysis in the external validation sample.
Raw score of each test was used in the statistical analyses for development of the PASC model. Z-scores were 
used to compute the PASC score. The K-TMT-E part B was log-transformed for accuracy of the estimate due 
to its large range (0–300) and non-normality. Multiple imputation and full information maximum likelihood 
estimations were used to treat missing values.
IBM SPSS (version 25.0, SPSS Statistics/IBM Corp, Armonk NY, USA) was used for the statistical analyses. 
For comparisons of latent means between the groups, maximum likelihood estimation was analyzed by Mplus 
(version 8.0)50. However, due to the violation of normality, bias-corrected bootstraps were performed together.
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